Kai Yuan

List of Publications by Year
in descending order

12	221	1478505 6	1199594 12
papers	citations	h-index	g-index

13	13	13	250
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Selective inhibition of CDK4/6: A safe and effective strategy for developing anticancer drugs. Acta Pharmaceutica Sinica B, 2021, 11, 30-54.	12.0	66
2	Rh(III)-Catalyzed Cascade Annulation/Câ€“H Activation of o-Ethynylanilines with Diazo Compounds: One-Pot Synthesis of Benzo[a]carbazoles via 1,4-Rhodium Migration. Organic Letters, 2016, 18, 5236-5239.	4.6	61
3	Palladium-Catalyzed Cascade Heck Cyclization To Access Bisindoles. Organic Letters, 2018, 20, 3477-3481.	4.6	45
4	Discovery of novel and selective CDK4/6 inhibitors by pharmacophore and structure-based virtual screening. Future Medicinal Chemistry, 2020, 12, 1121-1136.	2.3	9
5	Discovery of Dual CDK6/PIM1 Inhibitors with a Novel Structure, High Potency, and Favorable Druggability for the Treatment of Acute Myeloid Leukemia. Journal of Medicinal Chemistry, 2022, 65, 857-875.	6.4	8
6	Computational discovery and biological evaluation of novel inhibitors targeting histone-lysine N-methyltransferase SET7. Bioorganic and Medicinal Chemistry, 2020, 28, 115372.	3.0	7
7	Targeting dual-specificity tyrosine phosphorylation-regulated kinase 2 with a highly selective inhibitor for the treatment of prostate cancer. Nature Communications, 2022, 13, .	12.8	6
8	Design, Synthesis, and Biological Evaluation of Icaritin Derivatives as Novel Putative DEPTOR Inhibitors for Multiple Myeloma Treatment. Journal of Medicinal Chemistry, 2021, 64, 14942-14954.	6.4	5
9	Discovery of novel and orally bioavailable CDK 4/6 inhibitors with high kinome selectivity, low toxicity and long-acting stability for the treatment of multiple myeloma. European Journal of Medicinal Chemistry, 2022, 228, 114024.	5.5	4
10	Discovery of Novel Phosphoinositide-3-Kinase Î± Inhibitors with High Selectivity, Excellent Bioavailability, and Long-Acting Efficacy for Gastric Cancer. Journal of Medicinal Chemistry, 2022, 65, 9873-9892.	6.4	4
11	Computational discovery, structural optimization and biological evaluation of novel inhibitors targeting transient receptor potential vanilloid type 3 (TRPV3). Bioorganic Chemistry, 2021, 114, 105093.	4.1	3
12	Design, synthesis, and biological evaluation of novel tetrahydroprotoberberine derivatives to reduce SREBPs expression for the treatment of hyperlipidemia. European Journal of Medicinal Chemistry, 2021, 221, 113522.	5.5	3